APA (7th ed.) Citation

Lockman, S., Brummel, S. S., Ziemba, L., Stranix-Chibanda, L., McCarthy, K., Coletti, A., . . . Whalen, F. (2021). Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): A multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet (British edition), 397(10281), 1276-1292. https://doi.org/10.1016/S0140-6736(21)00314-7

Chicago Style (17th ed.) Citation

Lockman, Shahin, et al. "Efficacy and Safety of Dolutegravir with Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy (IMPAACT 2010/VESTED): A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial." The Lancet (British Edition) 397, no. 10281 (2021): 1276-1292. https://doi.org/10.1016/S0140-6736(21)00314-7.

MLA (9th ed.) Citation

Lockman, Shahin, et al. "Efficacy and Safety of Dolutegravir with Emtricitabine and Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate, and Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate HIV Antiretroviral Therapy Regimens Started in Pregnancy (IMPAACT 2010/VESTED): A Multicentre, Open-label, Randomised, Controlled, Phase 3 Trial." The Lancet (British Edition), vol. 397, no. 10281, 2021, pp. 1276-1292, https://doi.org/10.1016/S0140-6736(21)00314-7.